| Literature DB >> 32547533 |
Werner J D Ouwendijk1, Lennard J M Dekker2, Henk-Jan van den Ham1,3, Tihana Lenac Rovis4, Erik S Haefner5, Stipan Jonjic4, Jürgen Haas6, Theo M Luider2, Georges M G M Verjans1.
Abstract
Herpes simplex virus 1 (HSV-1) and varicella-zoster virus (VZV) are two closely related human alphaherpesviruses that persistently infect most adults worldwide and cause a variety of clinically important diseases. Herpesviruses are extremely well adapted to their hosts and interact broadly with cellular proteins to regulate virus replication and spread. However, it is incompletely understood how HSV-1 and VZV interact with the host proteome during productive infection. This study determined the temporal changes in virus and host protein expression during productive HSV-1 and VZV infection in the same cell type. Results demonstrated the temporally coordinated expression of HSV-1 and VZV proteins in infected cells. Analysis of the host proteomes showed that both viruses affected extracellular matrix composition, transcription, RNA processing and cell division. Moreover, the prominent role of epidermal growth factor receptor (EGFR) signaling during productive HSV-1 and VZV infection was identified. Stimulation and inhibition of EGFR leads to increased and decreased virus replication, respectively. Collectively, the comparative temporal analysis of viral and host proteomes in productively HSV-1 and VZV-infected cells provides a valuable resource for future studies aimed to identify target(s) for antiviral therapy development.Entities:
Keywords: epidermal growth factor; herpes simplex virus 1; mass-spectrometry; retinal pigment epithelial cells; varicella-zoster virus
Year: 2020 PMID: 32547533 PMCID: PMC7273502 DOI: 10.3389/fmicb.2020.01179
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
FIGURE 1Temporal analysis of the HSV-1 proteome during productive infection of ARPE-19 cells by mass spectrometry. (A) Infectious virus titer in supernatant of HSV-1-infected ARPE-19 cells (F-strain, MOI = 1) at the indicated time points. Data shown indicate average ± SD of n = 2 independent experiments. (B–D) HSV-1-infected ARPE-19 cells (F-strain, MOI = 1) were analyzed by MS. Three independent experiments were performed. (B) Principal component analysis of MS results, with the first and second principal components (PC1, PC2) and their corresponding variances depicted on the x- and y-axis, respectively. (C) Heatmap showing average log2-fold change in HSV-1 protein expression. Major clusters of viral proteins are indicated by number and font color. Reported kinetic classes of HSV-1 proteins are indicated. (D) Relative protein expression (average ± SD log2-fold change) of viral proteins from each cluster.
FIGURE 2Temporal analysis of selected HSV-1 proteins during productive infection of ARPE-19 cells by western blotting. (A) HSV-1-infected ARPE-19 cells (F-strain, MOI = 1) were analyzed by WB using antibodies directed to the indicated five HSV-1 proteins. Two independent experiments were performed. hpi: hours post-infection. (B) Overlay of WB and MS results, with the different time points indicated on the x-axis, western blot normalized protein abundance (ratio average HSV-1 protein: β-actin protein signal intensity) on the left y-axis, and mass spectrometry log2-transformed protein abundances on the right y-axis. WB data: red line and circles indicate mean WB normalized protein abundances (RL2 and US6: n = 3 independent experiments; RS1 and US1: n = 2 independent experiments). MS data: gray triangles indicate individual values (n = 3 independent experiments) and gray line indicates mean protein abundance.
FIGURE 3Temporal analysis of the VZV proteome during productive infection of ARPE-19 cells by mass spectrometry. (A) Cell-free VZV titers obtained from VZV-infected ARPE-19 cells (cell free VZV EMC-1 strain, MOI = 1) at the indicated time points after infection. Data shown indicate average ± SD of n = 2 independent experiments. (B) Enumeration of the viral DNA – to – PFU ratio in ARPE-19 cells. Three independently generated cell-free HSV-1 and VZV stocks were used for DNA extraction and virus titration on ARPE-19 cells. Viral DNA load and infectious titers were determined by qPCR and plaque assay, respectively. Horizontal line indicates median. (C) 13C6-L-Lysine and 13C6-L-Arginine labeled ARPE-19 cells were infected with cell-free VZV (strain EMC-1, MOI = 1), in the presence of 13C6-L-Lysine and 13C6-L-Arginine to label newly synthesized proteins, and analyzed by MS. Three independent experiments were performed. (D) Principal component analysis of MS results, with PC1 and PC2 and their corresponding variances depicted on the x- and y-axis, respectively. (E) Heatmap showing average log2-fold change in VZV protein expression. ORF4, ORF61 and three major clusters of viral proteins are indicated by number and font color. Putative kinetic classes of VZV proteins, based on the kinetic class of their HSV-1 homologs, are indicated. (F) Relative protein expression (average ± SD log2-fold change) of viral proteins from each cluster, as well as ORFs 4 and 61.
FIGURE 4Temporal analysis of selected VZV proteins during productive infection of ARPE-19 cells by western blotting. (A,B) VZV-infected ARPE-19 cells (EMC-1, MOI = 1) were analyzed by WB using antibodies directed to the indicated five VZV proteins and human β-actin protein. Protein signal was visualized using fluorescence (A) and chemiluminescence (B). Two independent experiments were performed. Arrowhead indicates specific band corresponding to ORF8. (C) Overlay of WB and MS results, with the different time points indicated on the x-axis, western blot normalized protein abundance (ratio average VZV protein: β-actin protein signal intensity) on the left y-axis, and mass spectrometry log2-transformed protein abundances on the right y-axis. WB data: red line and circles indicate mean WB normalized protein abundances (n = 2 independent experiments). MS data: gray triangles indicate individual values (n = 3 independent experiments) and gray line indicates mean protein abundance.
FIGURE 5Temporal analysis of the host proteome during productive HSV-1 infection of ARPE-19 cells. Analysis of the host proteome in HSV-1-infected ARPE-19 cells (Figure 1) by MS. (A) Hierarchical cluster analysis of the virus and host proteins in HSV-1-infected cells. Viral proteins are indicated by red asterisks. Box indicates cluster containing majority of HSV-1 proteins. (B) Heatmap showing log2-fold change of up- and downregulated host (black font) proteins that clustered with virus proteins (green font) (box in panel A). (C) Number of differentially expressed host proteins in HSV-1-infected cells compared to mock-infected cells (adjusted p-value < 0.05). (D) Venn diagram indicating the number of significant differentially expressed host proteins at 6, 8, 10, and 12 hpi and the overlap between each set of proteins. (E) Heatmap showing log2-fold change of significant differentially expressed host proteins. (F) Cellular localization of host proteins that are up- and down-regulated during HSV-1 infection.
FIGURE 6Confirmation of up- and downregulated expression of selected host proteins during productive HSV-1 infection of ARPE-19 cells. (A) Volcano plot of host protein expression at 12 hpi compared to mock-infected cells. Log2-fold change protein expression is indicated on the x-axis and significance (log odds) on the y-axis. The 10 most significant differentially expressed proteins are indicated (gray squares: FDR > 0.1; blue squares: FDR < 0.1; red squares: FDR < 0.05). Bold red font: proteins selected for confirmation. (B) Log2-transformed SPARC and PLAA protein abundance during HSV-1 infection. (C–H) HSV-1.VP16-GFP (HSV-1-GFP)-infected ARPE-19 cells were analyzed at 24 hpi. (C) Protein lysates were probed with antibodies specific to GFP, SPARC and β-actin. (D) Signal intensity of SPARC and β-actin were quantified and the average ratios SPARC/β-actin (n = 4 experiments) ± SEM are shown. (E) Mock- and HSV-1-GFP-infected (green) cells were stained for SPARC (red). (F) Histogram showing PLAA expression in mock-infected (filled, gray) and HSV-1-infected cells (red line) by flow cytometry. Fluorescence minus one (FMO) controls are shown for uninfected (black line) and HSV-1-infected cells (dashed black line). (G) Median fluorescent intensity (MFI) ratio (PLAA-stained/FMO control) for HSV-1-infected and mock-infected cells (n = 3 experiments) ± SEM are shown. (H) Confocal microscopy pictures of uninfected and HSV-1-GFP-infected (green) cells stained for PLAA. (E,H) Representative image for n = 3 independent experiments; Scale bar: 10 μm; Nuclei were stained with Hoechst (blue). (D,G) * p < 0.05 by paired Student’s t-test.
Gene ontology enrichment analysis of host proteins affected by HSV-1 infectiona.
| GO:0043066∼negative regulation of apoptotic process | 6.66E-03 | 5.92 | ALB, BAG3, MTDH, PHB2, PPIF |
| GO:0030198∼extracellular matrix organization | 3.4E-04 | 6.70 | CCN1, ITGA5, LOX, SERPINE1, SPARC, TGFBI, THBS1 |
| GO:0007155∼cell adhesion | 8.7E-03 | 3.72 | CCN1, CD99, CNTN3, CTNNB1, ITGA5, THBS1, TGFBI |
| GO:0045944∼positive regulation of transcription from RNA polymerase II promoter | 1.0E-02 | 2.87 | CCN1, CTNNB1, DDX3X, FUBP3, IL18, PRKDC, SERPINE1, STAT1, YBX1 |
| GO:0071363∼cellular response to growth factor stimulus | 1.6E-02 | 6.96 | CTNNB1, CPNE3, SPARC, THBS1 |
| GO:0042060∼wound healing | 1.6E-02 | 6.96 | DCBLD2, LOX, SPARC, TPM1 |
| GO:0001701∼ | 2.4E-02 | 4.35 | CTNNB1, MAN2A1, TPM1, YBX1, YBX3 |
| GO:0016525∼negative regulation of angiogenesis | 2.4E-02 | 11.49 | SPARC, STAT1, THBS1 |
| GO:0001525∼angiogenesis | 2.7E-02 | 4.16 | ANXA2, IL18, ITGA5, SERPINE1, TGFBI |
| GO:0001937∼negative regulation of endothelial cell proliferation | 3.4E-02 | 9.58 | SPARC, STAT1, THBS1 |
FIGURE 7Temporal analysis of the host proteome during productive VZV infection of ARPE-19 cells. Analysis of the host proteome in VZV-infected ARPE-19 cells (Figure 3) by MS. (A) Hierarchical cluster analysis of the virus and host proteins in VZV-infected cells. Viral proteins are indicated by red asterisks. Box indicates cluster containing majority of VZV proteins. (B) Heatmap showing log2-fold change of up- and downregulated host (black font) proteins that clustered with virus proteins (green font) [box in panel (A)]. (C) Number of differentially expressed host proteins in VZV-infected cells compared to mock-infected cells (adjusted p-value < 0.05). (D) Venn diagram indicating the number of significant differentially expressed host proteins at 3, 6, 12, and 24 hpi and the overlap between each set of proteins. (E) Cellular localization of host proteins that are up- and down-regulated during VZV infection.
FIGURE 8Confirmation of up- and downregulated expression of selected host proteins during productive VZV infection of ARPE-19 cells. (A) Volcano plot of host protein expression at 3 and 24 hpi compared to mock-infected cells. Log2-fold change protein expression is indicated on the x-axis and significance (log odds) on the y-axis. The 10 most significant differentially expressed proteins are indicated (gray squares: FDR > 0.05; blue squares: FDR < 0.05; red squares: FDR < 0.01). Bold red font: proteins selected for confirmation. (B) Log2-transformed LOX and NLRP14 protein abundance during VZV infection. (C) Histogram showing LOX expression in uninfected (filled, gray) and cell-free VZV-infected ARPE-19 cells (red line) by flow cytometry. Fluorescence minus one (FMO) controls are shown for uninfected (black line) and VZV-infected cells (dashed black line). (D) Median fluorescent intensity (MFI) ratio (LOX-stained/FMO control) for VZV-infected and mock-infected cells (n = 3 experiments). (E,F) Confocal microscopy pictures of mock-infected or cell-free VZV.BAC-GFP (VZV-GFP; green) infected ARPE-19 cells stained for LOX (E) and NLRP14 (F) (red). Representative image for n = 3 independent experiments; Scale bar: 10 μm; Nuclei were counterstained with Hoechst (blue).
Gene ontology enrichment analysis of host proteins affected by VZV infectiona.
| GO:0042384∼cilium assembly | 5.39E-04 | 8.9 | ABCC4, C10orf90, EHD1, PCM1, RAB23, WDR19 |
| GO:0051301∼cell division | 5.77E-04 | 4.7 | AURKA, BRCC3, CCNB1, CDC23, KIFC1, MAPRE2, NEK2, USP16, ZFYVE19, |
| GO:0030198∼extracellular matrix organization | 6.47E-04 | 6.6 | COL4A1, COL4A2, COL5A2, FBN1, FN1, GFAP, HSPG2 |
| GO:0060271∼cilium morphogenesis | 6.15E-03 | 6.8 | EHD1, PCM1, RAB23, RO60, WDR19 |
| GO:0000086∼G2/M transition of mitotic cell cycle | 6.31E-03 | 6.7 | AKAP9, AURKA, CCNB1, NEK2, PCM |
| GO:0031145∼anaphase-promoting complex-dependent catabolic process | 8.78E-03 | 9.3 | AURKA, CCNB1, CDC23, PSMD8 |
| GO:0007067∼mitotic nuclear division | 1.07E-02 | 4.5 | AURKA, BRCC3, CDC23, MAPRE2, NEK2, USP16 |
| GO:0070537∼histone H2A K63-linked deubiquitination | 1.60E-02 | 123.0 | BRCC3, USP16 |
| GO:0007080∼mitotic metaphase plate congression | 1.68E-02 | 15.0 | CCNB1, CDC23, KIFC1 |
| GO:0002576∼platelet degranulation | 1.79E-02 | 7.2 | ABCC4, AHSG, APOA1, FN1 |
| GO:0006396∼RNA processing | 5.13E-05 | 10.5 | DDX17, DHX36, HNRNPH1, HNRNPF, LSM7, SUGP2, XRN2 |
| GO:0007155∼cell adhesion | 6.68E-05 | 4.1 | ALCAM, APP, CCN1, CCN2, CDH2, CTNNAL1, CTNNB1, DSG2, IGFBP7, LAMB2, LGALS3BP, PXN |
| GO:0002576∼platelet degranulation | 7.18E-05 | 9.9 | APLP2, APP, LAMP2, LGALS3BP, QSOX1, SPARC, TGFB2 |
| GO:0042060∼wound healing | 2.12E-04 | 11.0 | DCBLD2, EGFR, LOX, SPARC, TGFB2, TPM1 |
| GO:0000398∼mRNA splicing, via spliceosome | 7.99E-04 | 5.3 | BUD31, HNRNPA2B1, HNRNPH1, HNRNPH2, HNRNPF, LSM7, SRRT, YBX1 |
| GO:0006397∼mRNA processing | 1.39E-03 | 5.7 | CCAR2, HNRNPA2B1, HNRNPLL, QKI, SUGP2, XRN2, ZC3H14, |
| GO:0008285∼negative regulation of cell proliferation | 1.51E-03 | 3.7 | ADAMTS1, CTNNB1, CUL1, IGFBP7, ITGA1, NF2, PKP2, QSOX1, SOD2, TGFB2 |
| GO:0030198∼extracellular matrix organization | 2.20E-03 | 5.2 | APP, CCN1, ERO1A, ITGA1, LAMB2, LOX, SPARC, |
| GO:0098911∼regulation of ventricular cardiac muscle cell action potential | 2.41E-03 | 39.8 | DLG1,DSG2, PKP2 |
| GO:2001241∼positive regulation of extrinsic apoptotic signaling pathway in absence of ligand | 3.94E-03 | 31.3 | CTNNA1, DAPK3, TGFB2 |
Gene ontology enrichment analysis of proteins differentially expressed at 3 h after VZVa infection.
| GO:0030198∼extracellular matrix organization | 6,68E-04 | 8,42 | COL4A1, COL4A2, COL5A2, GFAP, FBN1, HSPG2 |
| GO:0070537∼histone H2A K63-linked deubiquitination | 0,0106 | 183,51 | BRCC3, USP16 |
| GO:1904714∼regulation of chaperone-mediated autophagy | 0,0177 | 110,11 | EEF1A2, GFAP |
| GO:0051180∼vitamin transport | 0,0177 | 110,11 | GC, APOA1 |
| GO:0038063∼collagen-activated tyrosine kinase receptor signaling pathway | 0,0212 | 91,75 | COL4A1, COL4A2 |
| GO:0030574∼collagen catabolic process | 0,0219 | 12,90 | COL4A1, COL4A2, COL5A2 |
| GO:0031102∼neuron projection regeneration | 0,0282 | 68,81 | GFAP. APOA1 |
| GO:0016559∼peroxisome fission | 0,0351 | 55,05 | MFF, ACOT8 |
| GO:0051301∼cell division | 0,0363 | 3,93 | BRCC3, ZFYVE19, NEK2, USP16, CDC23 |
| GO:0010501∼RNA secondary structure unwinding | 0,0182 | 95,40 | DHX36, DDX19A |
Host proteins affected by both HSV-1 and VZV infection.
| AHSG | Alpha-2-HS-glycoprotein | Upregulated |
| CTNNB1 | Catenin beta-1 | Downregulated |
| CYR61 | Cysteine-rich angiogenic inducer 61 | Downregulated |
| DCBLD2 | Discoidin, CUB and LCCL domain-containing protein 2 | Downregulated |
| G3BP2 | Ras GTPase-activating protein-binding protein 2 | Downregulated |
| LOX | Protein-lysine 6-oxidase | Downregulated |
| SPARC | Secreted protein acidic and rich in cysteine (also known as osteonectin) | Downregulated |
| TPM1 | Tropomyosin alpha-1 chain | Downregulated |
| TXNDC17 | Thioredoxin domain-containing protein 17 | Downregulated |
| YBX1 | Y-box-binding protein 1 | Downregulated |
| YBX3 | Y-box-binding protein 3 | Downregulated |
FIGURE 9Comparison of the host proteome during productive HSV-1 and VZV infection of ARPE-19 cells. (A) Protein-protein interaction network (STRING Database) analysis of the conserved 7 affected host proteins and the significant differentially expressed host proteins in the same Gene Ontology biological process (Tables 1, 2). (B) ARPE-19 cells were infected with VZV.BAC-GFP or HSV-1.VP16-GFP for 24 h, stimulated with the indicated dose of EGF for 30 min and analyzed by western blotting using antibodies directed to EGFR, phosphorylated EGFR (p-EGFR), GFP and β-actin. (C,D) Signal intensity of EGFR, p-EGFR and β-actin was quantified and the average ratios EGFR/β-actin (C, n = 5 experiments) and p-EGFR/β-actin (D; n = 3 experiments) ± SEM are shown. (E,F) ARPE-19 cells were infected with cell-free HSV-1.VP16-GFP or cell-free VZV.BAC-GFP for 4 h, treated with EGF (E) or specific EGF inhibitor AG 1478 (F) and GFP expression was analyzed at indicated times after infection by flow cytometry. Two independent experiments performed, data (average ± SEM) shown from one representative experiment (n = 3 replicates). *p < 0.05, **p < 0.01, ***p < 0.001 by one-way ANOVA and Bonferroni’s multiple comparison correction.